Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers
International Journal of Molecular Sciences · 20.06.2025 · 26 (13) · 5928
DOI: 10.3390/ijms26135928 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.06.2025. Verfasst von Maria Teresa Vietri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, University of Campania "Luigi Vanvitelli", S. Andrea delle Dame, Via L. De Crecchio, 7, 80138 Napoli, Italy. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Hereditary Breast and Ovarian Cancer Syndrome, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hereditary breast and ovarian cancer (HBOC) syndrome is primarily associated with mutations in BRCA1 and BRCA2, but increasing evidence links it to other malignancies, including male breast, prostate, and pancreatic cancers. Advances in genetic testing have led to the use of multigene panels, revealing that additional genes contribute to HBOC risk. We tested 280 patients with suspected HBOC using a multigene panel including BRCA1, BRCA2, and other genes involved in homologous recombination (HR) and additional DNA repair mechanisms. Variants were classified as pathogenic variants (PVs), variants of uncertain significance (VUS), or novel. In silico tools were used to predict the clinical relevance of VUS and novel variants. The clinical phenotype of families carrying a PV was evaluated. PVs were identified in 19.3% of patients: 8.9% in BRCA1/2 and 10.4% in other genes, mainly CHEK2, ATM, PALB2, and BRIP1. An additional 1.8% of cases harbored likely pathogenic VUS or novel variants according to bioinformatic prediction. Breast and ovarian cancer were the most frequent malignancies in our population, both in the BRCA group and in those with PVs in other susceptibility genes. Broad genetic testing beyond BRCA improves HBOC diagnostics, supports identification of at-risk families, and enables more personalized surveillance and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", S. Andrea delle Dame, Via L. De Crecchio, 7, 80138 Napoli, Italy.
- Unit of Clinical and Molecular Pathology, AOU University of Campania "Luigi Vanvitelli", S. Andrea delle Dame, Via L. De Crecchio, 7, 80138 Napoli, Italy.
- Oncology Unit, Vallo Della Lucania-Agropoli Hospital, ASL Salerno, Via F Cammarota, 84078 Vallo Della Lucania, Italy.
ORCID-Profile: Chiara Della Pepa
Zitieren
APA
Vietri, M. T., Della Pepa, C., Caliendo, G., Mignano, A., Albanese, L., Zitiello, M., Stilo, M., & Molinari, A. M. (2025). Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers. International Journal of Molecular Sciences, 26(13), 5928. https://doi.org/10.3390/ijms26135928
Vancouver
Vietri MT, Della Pepa C, Caliendo G, Mignano A, Albanese L, Zitiello M, et al. Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers. International Journal of Molecular Sciences. 2025;26(13):5928. doi:10.3390/ijms26135928
BibTeX
@article{Vietri2025,
author = {Vietri, Maria Teresa and Della Pepa, Chiara and Caliendo, Gemma and Mignano, Alessia and Albanese, Luisa and Zitiello, Marialaura and Stilo, Marianna and Molinari, Anna Maria},
title = {Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {13},
pages = {5928},
doi = {10.3390/ijms26135928}
}
EUVIMED